DEA Lists New Chemical Mixes Free from Drug Control Hassles
Published Date: 3/20/2026
Notice
Summary
The Drug Enforcement Administration (DEA) just updated which chemical mixes are officially exempt from strict drug rules between September 2024 and December 2025. Companies and labs using these chemicals should check the new list to see if their products are approved or denied. You’ve got until May 19, 2026, to share your thoughts, and no extra fees are involved—just a quick review and comment if you want!
Analyzed Economic Effects
5 provisions identified: 2 benefits, 3 costs, 0 mixed.
Listed preparations exempted from select CSA rules
The DEA accepted applications filed between September 1, 2024 and December 31, 2025 and determined that the specific preparations listed in Chart I are exempt, to the extent described in 21 CFR 1308.24, from application of sections 302, 303, 305, 306, 307, 308, 309, 1002, 1003, and 1004 of the Controlled Substances Act (21 U.S.C. 822-823, 825-829, and 952-954) and 21 CFR 1301.74. The exemptions apply only to the precise preparations and forms described in each application.
Bulk exempt products restricted to in-house use
For exempted bulk products, DEA determined they may only be used in-house by the manufacturer and may not be distributed for any purpose or transported to other facilities. This restriction is intended to limit diversion opportunities for larger bulk quantities.
Changes to prep or name require new application
DEA states that any change in the quantitative or qualitative composition of an exempt preparation, or a change in the trade name or other designation after the application date, requires a new application under 21 CFR 1308.24(h).
Exemption does not remove other CSA/CFR duties
DEA notes that the exemptions are limited to specific sections identified in 21 CFR 1308.24(a) and that all other requirements of the CSA and CFR still apply, including registration as an importer required by 21 U.S.C. 957.
Opportunity to comment by May 19, 2026
Interested persons may submit comments on this order electronically or by mail; comments must be submitted or postmarked on or before May 19, 2026. DEA encourages electronic submissions via Regulations.gov (reference Docket No. DEA-372).
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2026-05485 — CSX Transportation, Inc.-Discontinuance Exemption-in Cook County, Ill
CSX Transportation is stopping train service on a 1.32-mile rail line in Cook County, Illinois, because no local freight has used it in two years. The change starts April 19, 2026, unless someone steps up to keep it running by March 30. Workers affected by this will get job protections, and rerouting options are ready for any traffic that used the line.
Next: 2026-05487 — Fermi America LLC (dba Fermi America); Project Matador Advanced Energy and Intelligence Campus AP1000 Units 1-4, Project Matador Nuclear Units 1-4; Notice of Intent To Conduct Scoping Process and Prepare an Environmental Impact Statement
Fermi America wants to build and run four new advanced nuclear reactors at the Project Matador campus. The Nuclear Regulatory Commission is starting a 30-day public comment period to gather ideas and concerns before deciding if they’ll approve the project. This is a big deal for local communities and the environment, with feedback due by April 20, 2026.